Skip to main content

Advertisement

Table 2 Baseline clinical characteristics and associated mortality and opportunistic infections of HIV-infected patients in Jimma University Specialized Hospital, between January 2006 and December 2011

From: Nutritional status and its effect on treatment outcome among HIV infected clients receiving HAART in Ethiopia: a cohort study

Characteristics Number of patients (%) Number of deaths (%) Number of OI (%)
WHO clinical stage
 Stage I 65 (19.1) 6 (14.3) 15 (18.1)
 Stage II 95 (27.9) 9 (21.4) 15 (18.1)
 Stage III 144 (42.4) 17 (40.5) 44 (53.0)
 Stage IV 36 (10.6) 10 (23.8) 9 (10.8)
HAART regimen
 Stavudine based 219 (64.4) 19 (45.2) 60 (72.3)
 Zidovudine based 72 (21.2) 12 (28.6) 18 (21.7)
 Tenofovir based 49 (14.4) 11 (26.2) 5 (6.0)
Base line CD4
 >350 5 (1.5) 0 (0.0) 2 (2.4)
 200–350 94 (27.6) 7 (16.7) 19 (22.9)
 100–199 139 (40.9) 15 (35.7) 37 (44.6)
 <100 102 (30.0) 20 (47.6) 25 (30.1)
Risky behaviour
 Yes 120 (35.3) 14 (33.3) 58 (69.9)
 No 220 (64.7) 28 (67.7) 25 (30.1)
Cotrimoxazole prophylaxis
 Yes 330 (97.1) 42 (100.0) 81 (97.6)
 No 10 (2.9) 0 (0.0) 2 (2.4)
Fluconazole prophylaxis
 Yes 20 (5.9) 8 (19.1) 5 (6.0)
 No 320 (94.1) 34 (80.9) 78 (94.0)
INH prophylaxis
 Yes 62 (18.2) 7 (16.7) 20 (24.1)
 No 278 (81.8) 35 (83.3) 63 (75.9)